



Validation of an ELISA method for the detection of anti-host cell antibodies in human serum

Aim of the study

Biopharmaceutical products may contain host cell derived protein impurities at low levels. A method for the detection of antibodies to HCP in human serum of patients treated with recombinant drug protein was validated for immunogenicity assessment.

Analyte

Anti-host cell antibodies.

Methodology

The ELISA method consists in a direct ELISA using antigen-coated microwell plates, while the detection system is a mixture of commercial HRP conjugated antibodies. Positive samples are confirmed by titration and specificity tests.

The ELISA method was tested for sensitivity, specificity, intra- and inter-run accuracy and precision, and for inter-operator variability using spiked quality control samples. System Human serum Therapeutic area Reproductive Medicine Development stage Preclinical Customer Large pharmaceutical company

Results

The ELISA method for detection in human serum of antibodies against host cell proteins of a recombinant protein produced in serum free medium was demonstrated to be accurate, precise, capable to confirm positive samples and sensitive and selective for the antigen.

Advantage of the methodology

Anti-host cell antibodies can activate immunogenic reactions in treated patients. Here, an accurate, precise and selective ELISA method was validated to detect the presence of these antibodies in patient serum.



CONTACT US:

ABLE Biosciences is part of **GEM FORLAB Srl** Registered and administrative office: Via Maestri del Lavoro, 25 12022 Busca (CN) Business office: Via Ribes, 5 - 10010 Colleretto Giacosa (TO) (c/o Bioindustry Park - Building U) VAT No./Tax Code 03701860045 Ph. +39 0125 53915 - Fax 0171/944810 E-mail: info@gemforlab.com WEB: http://www.gemforlab.com